Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 10.522
Filtrer
1.
Clin Lab Med ; 44(3): 527-539, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39089756

RÉSUMÉ

The term 'routine coagulation' typically applies to hemostasis tests routinely performed in hematology laboratories, often available 24/7, and potentially ordered urgently. These tests would comprise of the prothrombin time (PT), the PT converted to an international normalized ratio, the activated partial thromboplastin time (often called partial thromboplastin time in North American laboratories) and potentially the thrombin time, the D-dimer assay, and fibrinogen assays. Although other tests could feasibly be offered (testing feasible), there are good reasons for not including all of these other tests in all routine coagulation laboratories.


Sujet(s)
Temps de prothrombine , Humains , Tests de coagulation sanguine , Coagulation sanguine , Temps partiel de thromboplastine , Troubles de l'hémostase et de la coagulation/diagnostic , Troubles de l'hémostase et de la coagulation/sang , Produits de dégradation de la fibrine et du fibrinogène/analyse
2.
Scand Cardiovasc J ; 58(1): 2387001, 2024 Dec.
Article de Anglais | MEDLINE | ID: mdl-39092557

RÉSUMÉ

OBJECTIVES: This study aims to identify the risk factors contributing to in-hospital mortality in patients with acute ST-elevation myocardial infarction (STEMI) who develop acute heart failure (AHF) post-percutaneous coronary intervention (PCI). Based on these factors, we constructed a nomogram to effectively identify high-risk patients. METHODS: In the study, a collective of 280 individuals experiencing an acute STEMI who then developed AHF following PCI were evaluated. These subjects were split into groups for training and validation purposes. Utilizing lasso regression in conjunction with logistic regression analysis, researchers sought to pinpoint factors predictive of mortality and to create a corresponding nomogram for forecasting purposes. To evaluate the model's accuracy and usefulness in clinical settings, metrics such as the concordance index (C-index), calibration curves, and decision curve analysis (DCA) were employed. RESULTS: Key risk factors identified included blood lactate, D-dimer levels, gender, left ventricular ejection fraction (LVEF), and Killip class IV. The nomogram demonstrated high accuracy (C-index: training set 0.838, validation set 0.853) and good fit (Hosmer-Lemeshow test: χ2 = 0.545, p = 0.762), confirming its clinical utility. CONCLUSION: The developed clinical prediction model is effective in accurately forecasting mortality among patients with acute STEMI who develop AHF after PCI.


Sujet(s)
Techniques d'aide à la décision , Défaillance cardiaque , Mortalité hospitalière , Nomogrammes , Intervention coronarienne percutanée , Valeur prédictive des tests , Infarctus du myocarde avec sus-décalage du segment ST , Humains , Infarctus du myocarde avec sus-décalage du segment ST/mortalité , Infarctus du myocarde avec sus-décalage du segment ST/diagnostic , Infarctus du myocarde avec sus-décalage du segment ST/thérapie , Infarctus du myocarde avec sus-décalage du segment ST/sang , Défaillance cardiaque/mortalité , Défaillance cardiaque/diagnostic , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/mortalité , Mâle , Femelle , Appréciation des risques , Sujet âgé , Adulte d'âge moyen , Facteurs de risque , Résultat thérapeutique , Reproductibilité des résultats , Facteurs temps , Produits de dégradation de la fibrine et du fibrinogène/analyse , Débit systolique , Fonction ventriculaire gauche , Études rétrospectives , Acide lactique/sang , Facteurs sexuels
3.
BMC Pediatr ; 24(1): 496, 2024 Aug 02.
Article de Anglais | MEDLINE | ID: mdl-39095744

RÉSUMÉ

BACKGROUND: Necrotizing pneumonia (NP) is a rare serious complication of community-acquired pneumonia (CAP) in children, which is characterized by a protracted course of the disease and a prolonged hospital stay. This study aimed to assess the role of systemic immune-inflammatory index and systemic inflammatory response index in predicting early lung necrotization in children with CAP. METHODS: This study included all children hospitalized in Pediatric Pulmonology Unit, Tanta University, Egypt, with CAP between the ages of two months and 18 years. Systemic inflammatory indices, including the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR), systemic immune-inflammatory index (SII), and systemic inflammation response index (SIRI), were calculated on patients' admission. RESULTS: The study involved a total of 228 children, 42 patients had NP, 46 patients had parapneumonic effusion, and 140 patients had non-complicated CAP. Patients with NP were substantially younger (p = 0.002), stayed in the hospital longer (p < 0.001), had a longer duration of symptoms before hospital admission (p < 0.001), and had fever for a longer duration than those in the other groups (p < 0.001). Regarding the inflammatory ratios, patients with NP had significantly higher MLR, PLR, SII, and SIRI than those in the other groups (p = 0.020, p = 0.007, p = 0.001, p = 0.037, respectively). ROC curve analysis showed that the combined SII + SIRI + D-dimer showed the highest AUC with a good specificity in predicting the diagnosis of NP. CONCLUSIONS: SII, SIRI, and D-dimer may be beneficial biomarkers for predicting the occurrence of NP in children when performed on patients' admission. In addition, it was found for the first time that combined SII + SIRI + D-dimer had a good sensitivity and specificity in the diagnosis of NP.


Sujet(s)
Infections communautaires , Pneumonie nécrosante , Humains , Mâle , Femelle , Enfant d'âge préscolaire , Enfant , Nourrisson , Pneumonie nécrosante/diagnostic , Adolescent , Infections communautaires/diagnostic , Infections communautaires/sang , Granulocytes neutrophiles , Produits de dégradation de la fibrine et du fibrinogène/analyse , Numération des plaquettes , Courbe ROC , Marqueurs biologiques/sang , Numération des lymphocytes
4.
J Int Med Res ; 52(8): 3000605241266550, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39088659

RÉSUMÉ

OBJECTIVE: We aimed to describe clinical and laboratory characteristics and determine the predictors of outcome in patients with cerebral venous sinus thrombosis. METHODS: This prospective study was conducted over 2 years among hospitalized patients with cerebral venous sinus thrombosis. Patient outcome was assessed using the Modified Rankin Scale (mRS) score at 3 months. Outcome predictors were identified using logistic regression analysis. RESULTS: Eighty-one patients were included in this study. The median mRS outcome at 3 months was 1 (interquartile range 1-3). Poor outcomes were observed in 27.2% of patients, and the mortality rate was 9.8%. Factors associated with poor outcomes were age >60 years (relative risk [RR] 5.1), hemiparesis (RR 5.4), altered level of consciousness (RR 7.1), and transverse sinus involvement (RR 1.1). In general, mRS scores were not associated with D-dimer levels (RR 2.4). However, older patients with elevated D-dimer levels showed a significant association with poor outcomes (1.6) according to mRS scores. CONCLUSION: Older age, hemiparesis, and altered consciousness levels were independent predictors of poor outcomes in patients with cerebral venous sinus thrombosis. High D-dimer level showed no association with functional disability, except in older patients.


Sujet(s)
Produits de dégradation de la fibrine et du fibrinogène , Thromboses des sinus intracrâniens , Humains , Femelle , Mâle , Thromboses des sinus intracrâniens/diagnostic , Thromboses des sinus intracrâniens/mortalité , Adulte d'âge moyen , Adulte , Bangladesh/épidémiologie , Études prospectives , Produits de dégradation de la fibrine et du fibrinogène/analyse , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Pronostic , Orientation vers un spécialiste , Sujet âgé , Facteurs de risque , Parésie/étiologie
5.
CNS Neurosci Ther ; 30(8): e14861, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39097912

RÉSUMÉ

BACKGROUND AND PURPOSE: More evidence supports the benefits of batroxobin combined with anticoagulation in correcting acute cerebral venous thrombosis (CVT). The dynamic fluctuations of peripheral blood platelets, fibrinolysis, and coagulation biomarkers during this therapy were analyzed. METHODS: We investigated batroxobin's effects on the antithrombotic system under two regimens. The pretreatment group included patients on anticoagulants for at least 1 week before starting batroxobin. The simultaneous treatment group began both treatments upon admission. The control group received only anticoagulation. Batroxobin was given on alternate days at doses of 10BU, 5BU, and 5BU, totaling three doses. Anticoagulation was continuous. Baseline data were T0; the next day after each batroxobin dose was T1, T2, and T3. Data from these four time points was analyzed. RESULTS: The time-point paired sample T-test results of the pretreatment group [n = 60; mean age (SD), 43.3(16.5); 38 (63.35%) women] showed that batroxobin significantly inhibited ADP-induced platelet aggregation rate (T1-T0: p = 0.015; T2-T0: p = 0.025; T3-T0: p = 0.013), decreased fibrinogen level (T1-T0: p < 0.001; T2-T0: p < 0.001; T3-T0: p < 0.001), and increased D-dimer (T1-T0:p < 0.001; T2-T0: p < 0.001; T3-T0: p < 0.001), TT (T1-T0:p = 0.046; T2-T0: p = 0.003; T3-T0: p < 0.001), and APTT (T1-T0:p = 0.021; T2-T0: p = 0.012; T3-T0: p = 0.026). Compared to the control group, the simultaneous treatment group showed significantly higher TT (T2: p = 0.002; T3: p = 0.004) and D-dimer (T1: p < 0.001; T2: p < 0.001; T3: p < 0.001) values, while fibrinogen (T2: p < 0.001; T3: p < 0.001) levels were significantly lower. Using batroxobin can alleviate the amplitude of changes in coagulation indicators other than TT caused by anticoagulants. The above conclusions are consistent with the results of repeated measurement data analysis. CONCLUSIONS: Batroxobin can significantly inhibit ADP-induced platelet aggregation rate, increase D-dimer, decrease fibrinogen, and prolong TT and APTT in the presence of anticoagulant agents. Using batroxobin can reduce the amplitude of changes in coagulation indicators caused by anticoagulants. These results reveal the potential mechanism of batroxobin combined with anticoagulation in the safe and effective treatment of CVT.


Sujet(s)
Batroxobine , Thrombose intracrânienne , Thrombose veineuse , Humains , Batroxobine/pharmacologie , Mâle , Femelle , Adulte d'âge moyen , Adulte , Thrombose intracrânienne/traitement médicamenteux , Thrombose intracrânienne/sang , Thrombose veineuse/traitement médicamenteux , Fibrinolytiques/pharmacologie , Fibrinolytiques/usage thérapeutique , Agrégation plaquettaire/effets des médicaments et des substances chimiques , Anticoagulants/pharmacologie , Anticoagulants/usage thérapeutique , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Sujet âgé , Plaquettes/effets des médicaments et des substances chimiques , Plaquettes/métabolisme
7.
PLoS One ; 19(8): e0308178, 2024.
Article de Anglais | MEDLINE | ID: mdl-39093899

RÉSUMÉ

OBJECTIVE: To construct a stable rat portal vein thrombosis (PVT) model and explore the time window of urokinase thrombolytic therapy on this basis. METHODS: Constructing a rat PVT model by combining anhydrous ethanol disruption of portal endothelium with stasis of blood flow. Forty-eight rats after PVT modeling were divided into control group and experimental group, with 24 rats in each group. The experimental and control groups were given urokinase treatment and saline tail vein injection, respectively. The two groups of rats were observed and compared for PVT formation at 1, 3 and 5 days after modeling, respectively. RESULTS: A stable rat PVT model was successfully constructed. No significant differences were found in PVT length, portal vein wet weight, and percentage of luminal occlusion area in the control rats at 1, 3, and 5 days after successful modeling (P > 0.05). Compared with control rats 1 day after modeling, the percentage of non-organized thrombus luminal area was significantly decreased (P < 0.0001), and the percentage of organized thrombus luminal area was significantly increased (P < 0.0001) in the PVTs of control rats at 3 and 5 days after modeling. After thrombolytic treatment with urokinase, plasma fibrinogen (FBG) levels were significantly decreased in the experimental group of rats compared with the control group (P < 0.0001), and plasma D-dimer (D2D) levels were significantly increased in the experimental group of rats compared with the control group (P < 0.0001). In addition, we observed prolongation of prothrombin time (PT) in the experimental group at 1, 3 and 5 days after modeling compared to the control group (P = 0.0001). Compared with the control group, portal vein wet weight and PVT length were significantly decreased in the experimental group of rats at 1 day after modeling (P < 0.05), whereas these differences were not found in the two groups of rats at 3 and 5 days after modeling (P > 0.05). The percentage of non-organized thrombus area in the experimental group was significantly decreased compared with that in the control group at 1, 3, and 5 days after modeling (P < 0.05), whereas there was no significant difference in the percentage of lumen area of organized thrombus between the two groups (P > 0.05). CONCLUSION: The method of producing a rat PVT model by destroying the endothelium of the portal vein by anhydrous ethanol combined with blood flow stasis is feasible and reproducible. In addition, the optimal time window for thrombolysis in the treatment of PVT in rats using urokinase is the early stage of thrombosis, when the fibrin content is highest.


Sujet(s)
Modèles animaux de maladie humaine , Veine porte , Traitement thrombolytique , Activateur du plasminogène de type urokinase , Thrombose veineuse , Animaux , Veine porte/effets des médicaments et des substances chimiques , Thrombose veineuse/traitement médicamenteux , Rats , Activateur du plasminogène de type urokinase/métabolisme , Traitement thrombolytique/méthodes , Mâle , Rat Sprague-Dawley , Fibrinolytiques/pharmacologie , Fibrinolytiques/usage thérapeutique , Fibrinogène/métabolisme , Produits de dégradation de la fibrine et du fibrinogène/métabolisme
8.
Immun Inflamm Dis ; 12(8): e1373, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39150240

RÉSUMÉ

BACKGROUND: This study investigated clinical and laboratory characteristics of human bocavirus type 1 (HBoV1)-plastic bronchiolitis (PB), Mycoplasma pneumoniae (MP)-associated plastic bronchitis (PB) and MP-NPB in children, highlighting inflammation, coagulation, and bronchoscopic needs. METHODS: Data on preschool children with PB during HBoV1 or MP infection were collected, comparing MP-PB to severe Mycoplasma pneumoniae pneumonia. RESULT: Compared with the MP-PB group, the HBoV1-PB group, with younger children, had significantly milder clinical symptoms but higher WBC counts (p = .028). The MP-PB group exhibited notably elevated Fibrinogen (p = .045) and d-dimer levels (p < .001). When contrasting the MP-PB with the MP-NPB group, children in MP-PB group still had higher levels of d-dimer and increased inflammatory indicators such as C-reactive protein, procalcitonin, lactate dehydrogenase, and interleukin-6, which were significantly elevated compared with the MP-NPB group. MP-PB showed a higher prevalence of plastic bronchial casts in lower lobes (p = .016) and a dominance of neutrophils in BALF cytology. Additionally, children in the MP-PB group tended to undergo a greater number of bronchoscopies. CONCLUSION: This study identifies key differences in plastic bronchitis in children due to HBoV1 and MP, highlighting HBoV1's milder inflammation in younger kids and MP's link to severe inflammatory and coagulation responses, guiding clinical diagnosis and treatment.


Sujet(s)
Bronchite , Mycoplasma pneumoniae , Pneumopathie à mycoplasmes , Humains , Enfant d'âge préscolaire , Mâle , Femelle , Bronchite/microbiologie , Bronchite/diagnostic , Bronchite/virologie , Pneumopathie à mycoplasmes/sang , Pneumopathie à mycoplasmes/immunologie , Nourrisson , Infections à Parvoviridae/immunologie , Infections à Parvoviridae/complications , Infections à Parvoviridae/diagnostic , Bocavirus humain , Bronchiolite/virologie , Bronchiolite/microbiologie , Enfant , Liquide de lavage bronchoalvéolaire/virologie , Liquide de lavage bronchoalvéolaire/microbiologie , Produits de dégradation de la fibrine et du fibrinogène/analyse , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Protéine C-réactive/analyse
9.
Clin Appl Thromb Hemost ; 30: 10760296241271331, 2024.
Article de Anglais | MEDLINE | ID: mdl-39135435

RÉSUMÉ

The purpose of this study is to investigate the risk factors for postoperative deep vein thrombosis (DVT) in patients with traumatic spinal fractures complicated with Spinal Cord Injury(SCI). We conducted a retrospective analysis of 110 patients with traumatic spinal fractures and SCI admitted to our hospital from March 2021 to April 2024. DVT was diagnosed using ultrasound. Patient history, general data, surgical data, laboratory tests, and thromboelastogram (TEG) results were collected. The patients were divided into a DVT group and a non-DVT group according to the results of ultrasound one week after surgery. The risk factors and diagnostic value were analyzed using binary logistic regression and receiver operating characteristic (ROC) curves in both univariate and multivariate analyses. Multivariate and ROC analysis results showed that D-dimer, lower extremity, duration of bedrest, and MA values of TEG were independent risk factors for DVT in SCI, with D-dimer having the highest diagnostic value (AUC = 0.883). The AUC values for lower extremity, duration of bedrest, and MA were 0.731, 0.750, and 0.625. In conclusion, Postoperative D-dimer > 5.065 mg/l, lower extremity < 3, duration of bedrest, and MA value of TEG are independent risk factors for postoperative DVT in SCI patients, D-dimer having the highest diagnostic value. When the above risk factors occur, clinicians need to be vigilant and take appropriate prevention and treatment measures.


Sujet(s)
Complications postopératoires , Traumatismes de la moelle épinière , Fractures du rachis , Thrombose veineuse , Humains , Thrombose veineuse/étiologie , Thrombose veineuse/sang , Facteurs de risque , Mâle , Femelle , Traumatismes de la moelle épinière/complications , Adulte d'âge moyen , Fractures du rachis/chirurgie , Fractures du rachis/sang , Complications postopératoires/étiologie , Complications postopératoires/sang , Adulte , Études rétrospectives , Produits de dégradation de la fibrine et du fibrinogène/analyse , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Sujet âgé
10.
BMJ Open ; 14(8): e087130, 2024 Aug 09.
Article de Anglais | MEDLINE | ID: mdl-39122395

RÉSUMÉ

INTRODUCTION: Large-vessel occlusion (LVO) stroke is effectively treated by time-critical thrombectomy, a highly specialised procedure only available in a limited number of centres. Many patients with suspected stroke are admitted to their nearest hospital and require transfer to access treatment, with resulting delays. This study is evaluating the accuracy of a new rapid portable test for LVO stroke which could be used in the future to select patients for direct admission to a thrombectomy centre. METHODS AND ANALYSIS: Rapid Assay Diagnostic for Acute Stroke Recognition (RADAR) is a prospective observational cohort study taking place in stroke units in England. Participants are adults with a new suspected stroke with at least one face, arm or speech (FAST) symptom(s) and known onset within 6 hours or last known to be well 6-24 hours ago. The index test ('LVOne test' (Upfront Diagnostics)), consists of two portable lateral flow assays which use fingerprick capillary blood to detect d-dimer and glial fibrillary acidic protein concentrations. Reference standards comprise independently adjudicated standard CT/MRI brain±CT/MR angiography with senior clinician opinion to establish: ischaemic stroke±LVO; intracerebral haemorrhage; transient ischaemic attack; stroke mimic. Analyses will report sensitivity, specificity and negative and positive predictive values for identification of LVO stroke. Powered using a primary analysis population (≥2 FAST symptoms and known onset within 6 hours), 276 participants will detect a test specificity of 92%. The broader total study population which allows evaluation of the test for milder symptoms and unknown onset times is estimated to be 552 participants. ETHICS AND DISSEMINATION: Ethical (North East-Newcastle & North Tyneside 2 Research Ethics Committee (reference: 23/NE/0043), Health Research Authority and participating National Health Service Trust approvals are granted. Consent is required for enrolment. Dissemination of results will include presentations at conferences, publication in journals and plain English summaries. TRIAL REGISTRATION NUMBER: ISRCTN12414986.


Sujet(s)
Accident vasculaire cérébral , Humains , Études prospectives , Accident vasculaire cérébral/diagnostic , Produits de dégradation de la fibrine et du fibrinogène/analyse , Angleterre , Thrombectomie
11.
J Coll Physicians Surg Pak ; 34(8): 981-984, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39113520

RÉSUMÉ

OBJECTIVE: To investigate the frequency of deep vein thrombosis (DVT) in patients aged over 80 years on admission after intertrochanteric femur fracture and to explore the risk factors of DVT. STUDY DESIGN: Descriptive study. Place and Duration of the Study: Department of Orthopaedics, China-Japan Friendship Hospital, Beijing, China, from 1st January 2019 to 31st December 2022. METHODOLOGY: A group of patients aged over 80 years with intertrochanteric fracture were included according to the presence or absence of DVT confirmed by ultrasonography on admission. The patients were divided into the non-DVT and DVT groups. Clinical data were retrospectively compared between the two groups and analysed by multivariate logistic regression to screen risk factors of DVT. RESULTS: A total of 130 patients meeting the inclusion criteria were enrolled, and 37 of them had DVT on admission, with a prevalence of 28.5%, including 25 (67.6%) distal peripheral DVT, 11 (29.7%) proximal central DVT, and 1 (2.7%) mixed DVT. The American Society of Anaesthesiologists (ASA) classification, Charlson comorbidity index, the serum levels of D-dimer, fibrinogen degradation products, albumin, potassium, inorganic phosphorus, and calcium showed significant differences between the two groups (p <0.1). Multivariate analysis identified increased D-dimer (>6.005 mg/L), decreased albumin (<36.45 g/L), and reduced potassium (<3.650 mmol/L) as independent factors for DVT in aged intertrochanteric fracture patients (AIFPs). CONCLUSION: A high incidence of DVT was revealed in AIFPs, and elevated D-dimer levels, reduced albumin levels, and reduced potassium concentrations were shown to be correlated to DVT. KEY WORDS: Intertrochanteric fracture, Deep vein thrombosis, Aged patients, Risk factor, Multivariate logistic regression.


Sujet(s)
Fractures de la hanche , Thrombose veineuse , Humains , Thrombose veineuse/épidémiologie , Thrombose veineuse/étiologie , Femelle , Mâle , Fractures de la hanche/épidémiologie , Facteurs de risque , Sujet âgé de 80 ans ou plus , Études rétrospectives , Chine/épidémiologie , Prévalence , Produits de dégradation de la fibrine et du fibrinogène/analyse
12.
Front Immunol ; 15: 1418625, 2024.
Article de Anglais | MEDLINE | ID: mdl-39139559

RÉSUMÉ

Background: Abdominal aortic aneurysm (AAA) development is driven by inflammation, in particular myeloid cells, which represent attractive biomarker candidates. Yet to date, the maximum aortic diameter is the only clinically applied predictor of AAA progression and indicator for surgical repair. We postulated that aortic inflammation is reflected in a systemic change of monocyte populations, which we investigated regarding marker potential in AAA diagnosis and prognosis. Methods: We conducted a single-center retrospective cohort study in a diagnostic setting, measuring monocyte subsets by flow cytometry in peripheral blood samples of 47 AAA patients under surveillance, matched with 25 healthy controls and 25 patients with peripheral artery disease (PAD). In a prognostic setting, we acquired longitudinal data of 60 AAA patients including aneurysm growth assessment by computed tomography at 6-month intervals. Results: Blood levels of total monocytes, CD16+ monocytes and particularly intermediate monocytes were significantly increased in AAA patients versus healthy individuals and were also elevated compared to PAD patients. The combination of intermediate monocyte and D-dimer blood levels outperformed the individual diagnostic marker values. Additionally, the elevated concentrations of total monocytes, intermediate monocytes, and monocyte-platelet aggregates (MPA) were suited to predict rapid AAA progression over short-term periods of six months. Of note, MPA were identified as independent predictor of AAA disease progression in multivariable analysis. Conclusion: Circulating monocyte subsets are elevated in AAA patients and support diagnosis and prediction of aneurysm progression. Monocyte subsets and D-dimer reflect different hallmarks (inflammation and hemostasis) of AAA pathology and when combined, may serve as improved biomarker.


Sujet(s)
Anévrysme de l'aorte abdominale , Marqueurs biologiques , Monocytes , Humains , Anévrysme de l'aorte abdominale/sang , Anévrysme de l'aorte abdominale/diagnostic , Anévrysme de l'aorte abdominale/immunologie , Monocytes/immunologie , Mâle , Marqueurs biologiques/sang , Études rétrospectives , Femelle , Sujet âgé , Adulte d'âge moyen , Évolution de la maladie , Pronostic , Produits de dégradation de la fibrine et du fibrinogène/analyse , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Sujet âgé de 80 ans ou plus
13.
PeerJ ; 12: e17527, 2024.
Article de Anglais | MEDLINE | ID: mdl-38948205

RÉSUMÉ

Objective: Gastric cancer (GC), one of the highest venous thromboembolism (VTE) incidence rates in cancer, contributes to considerable morbidity, mortality, and, prominently, extra cost. However, up to now, there is not a high-quality VTE model to steadily predict the risk for VTE in China. Consequently, setting up a prediction model to predict the VTE risk is imperative. Methods: Data from 3,092 patients from December 15, 2017, to December 31, 2022, were retrospectively analyzed. Multiple logistic regression analysis was performed to assess risk factors for GC, and a nomogram was constructed based on screened risk factors. A receiver operating curve (ROC) and calibration plot was created to evaluate the accuracy of the nomogram. Results: The risk factors of suffering from VTE were older age (OR = 1.02, 95% CI [1.00-1.04]), Karnofsky Performance Status (KPS) ≥ 70 (OR = 0.45, 95% CI [0.25-0.83]), Blood transfusion (OR = 2.37, 95% CI [1.47-3.84]), advanced clinical stage (OR = 3.98, 95% CI [1.59-9.99]), central venous catheterization (CVC) (OR = 4.27, 95% CI [2.03-8.99]), operation (OR = 2.72, 95% CI [1.55-4.77]), fibrinogen degradation product (FDP) >5 µg/mL (OR = 1.92, 95% CI [1.13-3.25]), and D-dimer > 0.5 mg/L (OR = 2.50, 95% CI [1.19-5.28]). The area under the ROC curve (AUC) was 0.82 in the training set and 0.85 in the validation set. Conclusion: Our prediction model can accurately predict the risk of the appearance of VTE in gastric cancer patients and can be used as a robust and efficient tool for evaluating the possibility of VTE.


Sujet(s)
Nomogrammes , Tumeurs de l'estomac , Thromboembolisme veineux , Humains , Thromboembolisme veineux/épidémiologie , Thromboembolisme veineux/étiologie , Thromboembolisme veineux/diagnostic , Tumeurs de l'estomac/complications , Études rétrospectives , Mâle , Femelle , Adulte d'âge moyen , Facteurs de risque , Sujet âgé , Chine/épidémiologie , Appréciation des risques/méthodes , Courbe ROC , Produits de dégradation de la fibrine et du fibrinogène/analyse , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Adulte
14.
PLoS One ; 19(7): e0305163, 2024.
Article de Anglais | MEDLINE | ID: mdl-38976662

RÉSUMÉ

OBJECTIVE: To investigate the diagnostic value of D-dimer, platelet-lymphocyte rate (PLR) and CT signs for intestinal ischemia in patients with bowel obstruction. METHODS: We retrospectively analyzed the clinical and imaging data of 105 patients diagnosed with bowel obstruction, and performed univariate and multivariate analyses to determine the independent risk factors for intestinal ischemia in patients with bowel obstruction. Moreover, the receiver operating characteristic curve (ROC) was plotted to examine the diagnostic value of D-dimer, PLR and CT signs in patients with bowel obstruction. Besides, Kappa tests were used to assess inter-observer agreement. RESULTS: We included 56 men (53%) and 49 women (47%) with mean age of 66.05 ± 16 years. Univariate and multivariate analyses showed that D-dimer, PLR and two significant CT signs (i.e., increased unenhanced bowel-wall attenuation and mesenteric haziness) were independent risk factors for intestinal ischemia in patients with bowel obstruction. ROC analysis showed that the combined use of D-dimer, PLR and the said two CT signs had better performance than single indicators in predicting intestinal ischemia in patients with bowel obstruction. The area under the curve (AUC) of the joint model III was 0.925 [95%CI: 0.876-0.975], with a sensitivity of 79.2% [95CI%: 67.2-91.1] and a specificity of 91.2% [95%CI: 83.7-98.9]. CONCLUSION: The combined use of D-dimer, PLR and CT signs has high diagnostic value for intestinal ischemia in patients with bowel obstruction and will prompt surgical exploration to evaluate intestinal blood flow.


Sujet(s)
Produits de dégradation de la fibrine et du fibrinogène , Occlusion intestinale , Ischémie , Lymphocytes , Tomodensitométrie , Humains , Produits de dégradation de la fibrine et du fibrinogène/analyse , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Mâle , Femelle , Sujet âgé , Occlusion intestinale/sang , Occlusion intestinale/imagerie diagnostique , Occlusion intestinale/étiologie , Occlusion intestinale/diagnostic , Adulte d'âge moyen , Études rétrospectives , Ischémie/sang , Courbe ROC , Intestins/vascularisation , Intestins/anatomopathologie , Intestins/imagerie diagnostique , Plaquettes/anatomopathologie , Plaquettes/métabolisme , Numération des plaquettes , Numération des lymphocytes , Sujet âgé de 80 ans ou plus , Facteurs de risque
15.
BMC Nephrol ; 25(1): 223, 2024 Jul 12.
Article de Anglais | MEDLINE | ID: mdl-38997655

RÉSUMÉ

BACKGROUND: Cardiovascular diseases are the dominant cause of morbidity in hemodialysis (HD) patients. Unless sufficient anticoagulation is used during HD, clotting may appear. The objective was to investigate if levels of fibrin degradation products (D-dimer) were increased before and during HD. METHODS: The combined observational study included 20 patients performing a total of 60 hemodialysis divided into three sessions of low-flux dialysis. None of the patients suffered from any clinically evident thromboembolic event before or during the study. Median bolus anticoagulation (mainly tinzaparin) doses were 84 Units/kg bow. Blood samples were drawn before HD (predialysis), and at 30min and 180min during HD with focus on analyzing D-dimer levels and its relation to interdialytic weight gain (IDWG) and speed of fluid elimination by HD (UF-rate). RESULTS: Predialysis, D-dimer levels (mean 0.767 ±0.821, min 0.136mg/L) were above the upper reference value in 95% of the sessions. D-dimer levels were lowered at 30min (p<0.001) and returned to predialysis levels at 180min. Predialysis D-dimer correlated with NT-pro-BNP, Troponin T, IDWG and UF-rate. Multiple regression analysis revealed that the D-dimer levels were significantly related to IDWG and the UF-rate. CONCLUSIONS: D-dimer levels were elevated in a high proportion predialysis and during HD and related to the IDWG and the UF-rate. Awareness of D-dimer levels and future studies will help clarify if optimization of those variables, besides anticoagulation and biocompatibility measures, will eradicate the repeated subclinical thromboembolic events related to each HD; one reason that may explain organ damage and shortened life span of these patients.


Sujet(s)
Produits de dégradation de la fibrine et du fibrinogène , Dialyse rénale , Humains , Dialyse rénale/effets indésirables , Femelle , Mâle , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Produits de dégradation de la fibrine et du fibrinogène/analyse , Adulte d'âge moyen , Sujet âgé , Thrombose/étiologie , Thrombose/sang , Défaillance rénale chronique/thérapie , Défaillance rénale chronique/sang , Défaillance rénale chronique/complications , Anticoagulants/usage thérapeutique , Adulte
16.
Clin Lab ; 70(7)2024 Jul 01.
Article de Anglais | MEDLINE | ID: mdl-38965966

RÉSUMÉ

BACKGROUND: D-dimer, a specific product of cross-linked fibrin degradation, is of great clinical value in the early diagnosis of thrombotic diseases and in monitoring the efficacy of thrombolysis; therefore, the accuracy of D-dimer test results is crucial. METHODS: This article reports a case of a patient with disseminated intravascular coagulation (DIC) who experienced a false decrease in D-dimer due to the hook effect. RESULTS: The three D-dimer test results for DIC patients were 1.09 mg/L, 0.93 mg/L, and 1.43 mg/L. After sample dilution, the results were: first time (1:128) 842.24 mg/L, second time (1:128) 1,505.28 mg/L, third time (1:32) 415.68 mg/L. There was a significant difference in the three test results before and after dilution, because the D-dimer concentration was too high, exceeding the detection range and causing the hook effect, which falsely lowered the D-dimer value. CONCLUSIONS: When the D-dimer value of DIC patients does not match the clinical situation, the possibility of the hook effect should be considered, and the false decrease can be ruled out by the sample dilution method. In this way, accurate clinical results can be obtained to avoid delaying the diagnosis and treatment of DIC patients.


Sujet(s)
Coagulation intravasculaire disséminée , Produits de dégradation de la fibrine et du fibrinogène , Humains , Produits de dégradation de la fibrine et du fibrinogène/analyse , Coagulation intravasculaire disséminée/sang , Coagulation intravasculaire disséminée/diagnostic , Mâle , Femelle , Faux positifs , Adulte d'âge moyen , Sujet âgé , Faux négatifs
17.
Front Immunol ; 15: 1400526, 2024.
Article de Anglais | MEDLINE | ID: mdl-38953032

RÉSUMÉ

Background: Hereditary angioedema (HAE) is a rare disease characterized by localized and self-limited angioedema (AE) attacks. A local increase of bradykinin (BK) mediates AE attacks in HAE, however the role of inflammation in HAE has been poorly explored We aim to analyze the role of inflammatory mediators in HAE patients during AE attacks. Methods: Patients with a confirmed HAE diagnosis due to C1 inhibitor deficiency (HAE-C1INH) or patients F12 gene mutations (HAE-FXII) attending to our outpatient clinic between November-2019 and May-2022 were included. Demographic and clinical characteristics were analyzed. Blood samples were collected both during symptom-free periods (baseline) and during HAE attacks, and acute phase reactants (APR), such as serum amyloid A (SAA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D-Dimer and white blood cells were measured. Results: Seventy-eight patients were enrolled in the study, with a predominant representation of women (76%, n=59), and a mean age of 47.8 years (range 6-88). Among them, 67% (n=52) of patients had HAE-C1INH (46 classified as type 1 and 6 as type 2) while 33% (n=26) had HAE-FXII. During attack-free periods, the majority of patients exhibited normal levels of SAA, ESR, D-dimer, ACE and WCC. However, in a subset of patients (16% for SAA, 18% for ESR, and 14.5% for D-dimer), elevations were noted at baseline. Importantly, during HAE attacks, significant increases were observed in SAA in 88% of patients (p< 0.0001 vs. baseline), in ESR in 65% (p= 0.003 vs. baseline) and D-dimer in 71% (p=0.001 vs. baseline) of the patients. A comparison between baseline and acute attack levels in 17 patients revealed significant differences in SAA AA (p<0. 0001), ESR (p<0.0001) and D-dimer (p= 0.004). No significant differences were observed in CRP (p=0.7), ACE (p=0.67) and WCC (p=0.54). These findings remained consistent regardless of HAE type, disease activity or location of angioedema. Conclusion: The systemic increase in APR observed during HAE attacks suggests that inflammation extends beyond the localized edematous area. This finding underscores the potential involvement of inflammatory pathways in HAE and highlights the need for further investigation into their role in the pathophysiology of HAE.


Sujet(s)
Angio-oedèmes héréditaires , Marqueurs biologiques , Inflammation , Humains , Femelle , Mâle , Adulte , Angio-oedèmes héréditaires/sang , Angio-oedèmes héréditaires/diagnostic , Adulte d'âge moyen , Marqueurs biologiques/sang , Sujet âgé , Inflammation/sang , Adolescent , Enfant , Jeune adulte , Sujet âgé de 80 ans ou plus , C1 Inhibiteur/génétique , C1 Inhibiteur/métabolisme , Protéine amyloïde A sérique/métabolisme , Facteur XII/génétique , Facteur XII/métabolisme , Sédimentation du sang , Médiateurs de l'inflammation/sang , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Produits de dégradation de la fibrine et du fibrinogène/analyse
18.
BMC Pulm Med ; 24(1): 312, 2024 Jul 03.
Article de Anglais | MEDLINE | ID: mdl-38961438

RÉSUMÉ

BACKGROUND: The Omicron variant broke out in China at the end of 2022, causing a considerable number of severe cases and even deaths. The study aimed to identify risk factors for death in patients hospitalized with SARS-CoV-2 Omicron infection and to establish a scoring system for predicting mortality. METHODS: 1817 patients were enrolled at eight hospitals in China from December 2022 to May 2023, including 815 patients in the training group and 1002 patients in the validation group. Forty-six clinical and laboratory features were screened using LASSO regression and multivariable logistic regression. RESULTS: In the training set, 730 patients were discharged and 85 patients died. In the validation set, 918 patients were discharged and 84 patients died. LASSO regression identified age, levels of interleukin (IL) -6, blood urea nitrogen (BUN), lactate dehydrogenase (LDH), and D-dimer; neutrophil count, neutrophil-to-lymphocyte ratio (NLR) as associated with mortality. Multivariable logistic regression analysis showed that older age, IL-6, BUN, LDH and D-dimer were significant independent risk factors. Based on these variables, a scoring system was developed with a sensitivity of 83.6% and a specificity of 83.5% in the training group, and a sensitivity of 79.8% and a sensitivity of 83.0% in the validation group. CONCLUSIONS: A scoring system based on age, IL-6, BUN, LDH and D-dime can help clinicians identify patients with poor prognosis early.


Sujet(s)
COVID-19 , SARS-CoV-2 , Humains , COVID-19/mortalité , Mâle , Femelle , Adulte d'âge moyen , Chine/épidémiologie , Sujet âgé , Facteurs de risque , Hospitalisation/statistiques et données numériques , Adulte , Pronostic , Produits de dégradation de la fibrine et du fibrinogène/analyse , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Facteurs âges , Modèles logistiques , Granulocytes neutrophiles , Azote uréique sanguin , L-Lactate dehydrogenase/sang
19.
BMC Vet Res ; 20(1): 292, 2024 Jul 05.
Article de Anglais | MEDLINE | ID: mdl-38970022

RÉSUMÉ

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a crucial heart disease in cats. The clinical manifestations of HCM comprise pulmonary edema, dyspnea, syncope, arterial thromboembolism (ATE), and sudden cardiac death. D-dimer and prothrombin time (PT) are powerful biomarkers used to assess coagulation function. Dysregulation in these two biomarkers may be associated with HCM in cats. This study aims to assess D-dimer levels, PT, and proteomic profiling in healthy cats in comparison to cats with symptomatic HCM. RESULTS: Twenty-nine client-owned cats with HCM were enrolled, including 15 healthy control and 14 symptomatic HCM cats. The D-dimer concentration and PT were examined. Proteomic analysis was conducted by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry and liquid chromatography-tandem mass spectrometry (LC-MS/MS). In symptomatic cats, D-dimer levels were statistically significantly higher (mean ± SEM: 372.19 ng/ml ± 58.28) than in healthy cats (mean ± SEM: 208.54 ng/ml ± 10.92) with P-value of less than 0.01, while PT was statistically significantly lower in symptomatic cats (mean ± SEM: 9.8 s ± 0.15) compared to healthy cats (mean ± SEM: 11.08 s ± 0.23) with P-value of less than 0.0001. The proteomics analysis revealed upregulation of integrin subunit alpha M (ITGAM), elongin B (ELOB), and fibrillin 2 (FBN2) and downregulation of zinc finger protein 316 (ZNF316) and ectonucleoside triphosphate diphosphohydrolase 8 (ENTPD8) in symptomatic HCM cats. In addition, protein-drug interaction analysis identified the Ras signaling pathway and PI3K-Akt signaling pathway. CONCLUSIONS: Cats with symptomatic HCM have higher D-dimer and lower PT than healthy cats. Proteomic profiles may be used as potential biomarkers for the detection and management of HCM in cats. The use of D-dimer as a biomarker for HCM detection and the use of proteomic profiling for a better understanding of disease mechanisms remain to be further studied in cats.


Sujet(s)
Cardiomyopathie hypertrophique , Maladies des chats , Produits de dégradation de la fibrine et du fibrinogène , Protéomique , Animaux , Chats , Maladies des chats/sang , Cardiomyopathie hypertrophique/médecine vétérinaire , Cardiomyopathie hypertrophique/sang , Mâle , Femelle , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Produits de dégradation de la fibrine et du fibrinogène/analyse , Coagulation sanguine/physiologie , Temps de prothrombine/médecine vétérinaire , Marqueurs biologiques/sang , Spectrométrie de masse MALDI/médecine vétérinaire , Spectrométrie de masse en tandem/médecine vétérinaire
20.
Sci Rep ; 14(1): 15391, 2024 07 04.
Article de Anglais | MEDLINE | ID: mdl-38965325

RÉSUMÉ

In this study, We aim to explore the association between the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), systemic immune-inflammatory index (SII), lymphocyte to monocyte ratio (LMR) and prognostic nutritional index (PNI) and distant metastasis of gastric cancer and develop an efficient nomogram for screening patients with distant metastasis. A total of 1281 inpatients with gastric cancer were enrolled and divided into the training and validation set.Univariate, Lasso regression and Multivariate Logistic Regression Analysis was used to identify the risk factors of distant metastasis. The independent predictive factors were then enrolled in the nomogram model. The nomogram's predictive perform and clinical practicality was evaluated by receiver operating characteristics (ROC) curves, calibration curves and decision curve analysis. Multivariate Logistic Regression Analysis identified D-dimer, CA199, CA125, NLR and PNI as independent predictive factors. The area under the curve of our nomogram based on these factors was 0.838 in the training cohort and 0.811 in the validation cohort. The calibration plots and decision curves demonstrated the nomogram's good predictive performance and clinical practicality in both training and validation cohort. Therefore,our nomogram could be an important tool for clinicians in screening gastric cancer patients with distant metastasis.


Sujet(s)
Lymphocytes , Granulocytes neutrophiles , Nomogrammes , Évaluation de l'état nutritionnel , Tumeurs de l'estomac , Humains , Tumeurs de l'estomac/anatomopathologie , Tumeurs de l'estomac/sang , Mâle , Femelle , Granulocytes neutrophiles/anatomopathologie , Adulte d'âge moyen , Lymphocytes/anatomopathologie , Pronostic , Sujet âgé , Courbe ROC , Métastase tumorale , Numération des lymphocytes , Facteurs de risque , Produits de dégradation de la fibrine et du fibrinogène/métabolisme , Produits de dégradation de la fibrine et du fibrinogène/analyse , Adulte , Antigènes CA-125/sang , Antigènes glycanniques associés aux tumeurs
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE